174 related articles for article (PubMed ID: 34286946)
1. Prevention of type 1 diabetes: where we are and where we are going.
Frontino G; Guercio Nuzio S; Scaramuzza A; D'Annunzio G; Toni S; Citriniti F; Bonfanti R
Minerva Pediatr (Torino); 2021 Dec; 73(6):486-503. PubMed ID: 34286946
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.
Gaglia J; Kissler S
Biochemistry; 2019 Oct; 58(40):4107-4111. PubMed ID: 31523950
[TBL] [Abstract][Full Text] [Related]
3. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes.
Mignogna C; Maddaloni E; D'Onofrio L; Buzzetti R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1209-1219. PubMed ID: 34936848
[TBL] [Abstract][Full Text] [Related]
4. Teplizumab: First Approval.
Keam SJ
Drugs; 2023 Apr; 83(5):439-445. PubMed ID: 36877454
[TBL] [Abstract][Full Text] [Related]
5. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
6. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
7. Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
Felton JL
Immunohorizons; 2021 Jul; 5(7):535-542. PubMed ID: 34261674
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review.
LeFevre JD; Cyriac SL; Tokmic A; Pitlick JM
Am J Health Syst Pharm; 2022 Nov; 79(23):2099-2117. PubMed ID: 36056809
[TBL] [Abstract][Full Text] [Related]
9. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
10. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
11. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
[TBL] [Abstract][Full Text] [Related]
12. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
Tooley JE; Vudattu N; Choi J; Cotsapas C; Devine L; Raddassi K; Ehlers MR; McNamara JG; Harris KM; Kanaparthi S; Phippard D; Herold KC
Eur J Immunol; 2016 Jan; 46(1):230-41. PubMed ID: 26518356
[TBL] [Abstract][Full Text] [Related]
13. Teplizumab: type 1 diabetes mellitus preventable?
Misra S; Shukla AK
Eur J Clin Pharmacol; 2023 May; 79(5):609-616. PubMed ID: 37004543
[TBL] [Abstract][Full Text] [Related]
14. Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus.
Sharma N; Das DD; Chawla PA
Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38279734
[TBL] [Abstract][Full Text] [Related]
15. Changing the landscape for type 1 diabetes: the first step to prevention.
Dayan CM; Korah M; Tatovic D; Bundy BN; Herold KC
Lancet; 2019 Oct; 394(10205):1286-1296. PubMed ID: 31533907
[TBL] [Abstract][Full Text] [Related]
16. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
17. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
18. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
19. Teplizumab therapy for type 1 diabetes.
Masharani UB; Becker J
Expert Opin Biol Ther; 2010 Mar; 10(3):459-65. PubMed ID: 20095914
[TBL] [Abstract][Full Text] [Related]
20. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
